mk-0777

Small moleculeexperimental

Clinical trial activity

6 trials · 9 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
6
Phase 3
0
Phase 4
0

Earliest trial started Aug 1, 2002 (NCT00543920)

Timeline

2000s

  1. Jan 1, 2002

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CCn1ncnc1COc1nn2c(-c3ccccc3F)nnc2cc1C(C)(C)C
Mol. weight
395.44 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 7-(1,1-dimethylethyl)-6-(2-ethyl-2h-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo(4,3-b)pyridazine
  • l-830982
  • mk0777
  • mk0777
  • mk-0777
  • mk-0777
  • mk-0777
  • mk-0777
  • tpa023
  • tpa 023
  • tpa-023

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00505076Phase 2Jul 1, 2007Columbia University, Duke University, Harvard University, New York University, University of California, Los Angeles, University of Maryland, Washington University in St. Louis
NCT00129441Phase 2Aug 1, 2005Merck, University of Pittsburgh
NCT00546624Phase 2Nov 1, 2002Merck
NCT00539578Phase 2Sep 1, 2002Merck
NCT00703833Phase 2Sep 1, 2002Merck
NCT00543920Phase 2Aug 1, 2002Merck
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
MerckFor profit5412002
Columbia UniversityAcademic/Hospital1012007
Duke UniversityAcademic/Hospital1012007
Harvard UniversityAcademic/Hospital1012007
New York UniversityAcademic/Hospital1012007
University of California, Los AngelesAcademic/Hospital1112007
University of MarylandAcademic/Hospital1012007
University of PittsburghAcademic/Hospital1112005
Washington University in St. LouisAcademic/Hospital1012007
9 organizations
Page 1 / 1